Tocilizumab improves systemic rheumatoid vasculitis with necrotizing crescentic glomerulonephritis

Abstract We report a Japanese woman with systemic rheumatoid vasculitis (SRV) complicated by necrotizing crescentic glomerulonephritis (NCGN). Rheumatoid arthritis first occurred at the age of 19 years, followed by interstitial pneumonia, hepatitis, rheumatoid nodules, mononeuritis multiplex, and hy...

Full description

Saved in:
Bibliographic Details
Published in:Modern rheumatology 2015-01, Vol.25 (1), p.138-142
Main Authors: Iijima, Takashi, Suwabe, Tatsuya, Sumida, Keiichi, Hayami, Noriko, Hiramatsu, Rikako, Hasegawa, Eiko, Yamanouchi, Masayuki, Hoshino, Junichi, Sawa, Naoki, Takaichi, Kenmei, Oohashi, Kenichi, Fujii, Takeshi, Ubara, Yoshifumi
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal, Humanized - therapeutic use
Antirheumatic Agents - therapeutic use
Cytoplasm
Female
Glomerulonephritis - complications
Glomerulonephritis - drug therapy
Glomerulonephritis - pathology
Humans
Medical diagnosis
Middle Aged
Proteins
Rheumatoid arthritis
Rheumatoid Vasculitis - drug therapy
Rheumatoid Vasculitis - pathology
Rheumatology
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract We report a Japanese woman with systemic rheumatoid vasculitis (SRV) complicated by necrotizing crescentic glomerulonephritis (NCGN). Rheumatoid arthritis first occurred at the age of 19 years, followed by interstitial pneumonia, hepatitis, rheumatoid nodules, mononeuritis multiplex, and hypocomplementemia in chronological order. At the age of 51 years, rapidly progressive renal failure occurred with nephrotic proteinuria, and NCGN with subepithelial deposits was revealed by renal biopsy. Severe destructive changes of multiple joints and scleritis were detected, but anti-neutrophil cytoplasmic antibody was negative on enzyme-linked immunosorbent assays and indirect immunofluorescence. SRV was diagnosed due to involvement of multiple extra-articular organs. An anti-interleukin (IL)-6 receptor antibody (tocilizumab) was started at dosage of 280 mg (8 mg/kg) monthly. After 18 months, her serum creatinine decreased from 1.7 to 1.3 mg/dL, and urinary protein excretion declined from 5.2 to 1.2 g daily. Tocilizumab may be a therapeutic option for SRV associated with NCGN.
ISSN:1439-7595
1439-7609
DOI:10.3109/14397595.2013.874748